stockportfolio.pro
Stocks / CLOV vs SUPN
CLOV vs SUPN
Clover Health Investments, Corp. and Supernus Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Clover Health Investments, Corp. (CLOV) | Supernus Pharmaceuticals, Inc. (SUPN) | |
|---|---|---|
| Market cap | $2.6B | $2.6B |
| Revenue (latest FY) | $1.92B | $718.95M |
| Net income (latest FY) | $-85.55M | $-38.55M |
| Revenue growth (5y CAGR) | 23.4% | 6.7% |
| Net margin | -4.4% | -5.4% |
| Return on equity | -27.7% | -3.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 9 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CLOV — free Open SUPN — freeFrequently asked questions
Which is bigger, CLOV or SUPN?
Supernus Pharmaceuticals, Inc. is larger by market capitalization — $2.6B versus $2.6B.
Which grows faster, CLOV or SUPN?
Over the last five fiscal years, Clover Health Investments, Corp. grew revenue faster — 23.4%/yr versus 6.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.